These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34947904)

  • 1. Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection.
    Klaeske K; Lehmann S; Palitzsch R; Büttner P; Barten MJ; Jawad K; Eifert S; Saeed D; Borger MA; Dieterlen MT
    Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the immunological profile in rejection-free heart transplantation.
    Klaeske K; Lehmann S; Büttner P; Palitzsch R; Fischer J; Jawad K; Garbade J; Borger MA; Barten MJ; Dieterlen MT
    Transpl Immunol; 2020 Apr; 59():101259. PubMed ID: 31704267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation.
    Dieterlen MT; Klaeske K; Bernhardt AA; Borger MA; Klein S; Garbade J; Lehmann S; Ayuk FA; Reichenspurner H; Barten MJ
    Front Immunol; 2021; 12():676175. PubMed ID: 34447372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
    Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients.
    Sathya CJ; Sheshgiri R; Prodger J; Tumiati L; Delgado D; Ross HJ; Rao V
    Transpl Int; 2010 Jun; 23(6):641-8. PubMed ID: 20102553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
    Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
    Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
    Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired circulating dendritic cell reconstitution identifies rejecting recipients after clinical heart transplantation independent of rejection therapy.
    Athanassopoulos P; Vaessen LM; Balk AH; Takkenberg JJ; Maat AP; Weimar W; Bogers AJ
    Eur J Cardiothorac Surg; 2005 May; 27(5):783-9. PubMed ID: 15848314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
    Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
    Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
    Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
    Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation.
    Korucu B; Yeter H; Guz G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Apr; 43(1):101-107. PubMed ID: 35451298
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients.
    Liefeldt L; Waiser J; Bachmann F; Budde K; Friedersdorff F; Halleck F; Lachmann N; Peters R; Rudolph B; Ünlü S; Wu K; Glander P
    J Clin Med; 2024 Jul; 13(15):. PubMed ID: 39124572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.